Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging

有变形胃肠的基质肿瘤的 41 年的老女性被指 18F-FDG-positron 排放断层摄影术和计算断层摄影术(PET/CT ) 与 imatinib 在一个月前后扫描治疗(Glivec 收款机， Gleevec 收款机， Novartis，巴塞尔，瑞士) ，一个酷氨酸激酶禁止者(400 mg/d ) 。新陈代谢的反应在一月治疗前后被评估。最大的 standardised 举起价值(SUV ) 的减少是 79%( 从 9.8 ～ 2.1 ) 。正电子排放断层摄影术在 imatinib 治疗的一个月以后表明了完全的新陈代谢的反应。另外，以前的损害与花冠相比是计算机化的 tomographic 图象。根据 CT 图象在在治疗前后的肿瘤的尺寸没有差别。然而，新陈代谢的活动被禁止。18F-FDG-PET 是为对在有胃肠的基质肿瘤的病人的一个月 imatinib 治疗的反应的察觉的一个珍贵方法。

A 41-year old female with metastatic gastrointestinal stromal tumor was referred to 18F-FDG-positron emission tomography and computed tomography （PET/CT） scan before and after one-month treatment with imatinib （Glivec, Gleevec, Novartis, Basel, Switzerland）, a tyrosine kinase inhibitor （400 mg/d）. Metabolic response was evaluated before and after one month of therapy. The decrease of the maximum standardised uptake value （SUV） was 79% （from 9.8 to 2.1）. Positron emission tomography demonstrated complete metabolic response after one-month of imatinib treatment. Additionally, the previous lesion was compared with the coronal computerized tomographic image. There was no difference in the size of the tumor before and after therapy according to CT images. However, metabolic activity was inhibited. 18F-FDG-PEr is a valuable method for the detection of response to one-month imatinib treatment in patients with gastrointestinal stromal tumors.